Summary
Chemotherapy of the larval stage of Echinococcus granulosus in man with high oral doses of mebendazole has only been partly successful. In order to improve effective pharmacotherapy of this disease with mebendazole, the optimal time for blood sampling has been assessed and the mebendazole concentrations acting on the parasite have been compared with their viability. The optimal time for blood sampling was analysed in 14 patients during longterm treatment with mebendazole. The plasma level 4 h after the morning dose exhibited the best correlation with the average 24-h concentration, suggesting that the plasma level should be monitored 4 h after the morning dose. In 22 patients undergoing surgery for hydatid disease, the mebendazole concentration in cyst fluid was significantly correlated with its plasma level 4 h after the morning dose. In 13 of them the free drug concentration was determined by equilibrium dialysis and it was almost identical with the free mebendazole concentration in plasma. Results of viability tests in 12 cases revealed viable cysts in 6 cases and possibly viable cysts in 6 other cases. Even patients treated for more than 12 months still had viable cysts.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bekhti A, Nizet M, Capron M, Dessaint JP, Santoro F, Capron A (1980) Chemotherapy of human hydatid disease with mebendazole. Follow-up of 16 cases. Acta Gastroenterol Belg 43:48–65
Bekhti A, Schaaps, JP, Capron M, Dessaint JP, Santoro F, Capron A (1977) Treatment of hepatic hydatid disease with mebendazole: preliminary results in four cases. Br Med J 2:1047–1051
Beard TC, Rickard MD, Goodman HT (1978) Medical treatment of hydatids. Med J Austr 1:633–635
Braithwaite PA, Allan RJ, Dawson M, Roberts MS, Watson TR (1983) Cyst and host tissue concentrations of mebendazole in patients undergoing surgery for hydatid disease. Med J Austr 2:383–384
Brandimarte C, Attili AF, Cantafora A, De Martin GL, Giunchi G (1980) Serum and hydatid cystic fluid levels of mebendazole in patients with liver hydatidosis. Ital J Gastroenterol 12:212–213
Bryceson ADM, Cowie AGA, Macleod C, White S, Edwards D, Smyth JD, McManus DP (1982) Experience with mebendazole in the treatment of inoperable hydatid disease in England. Trans Roy Soc Trop Med Hyg 76:510–518
Coltorti EA, Varela-Diaz VM (1972) IgG levels and host specificity in hydatid cyst fluid. J Parasitol 58:753–756
Coltorti EA, Varela-Diaz VM (1974) Echinococcus granulosus: penetration of macromolecules and their localisation on the parasite membranes of cysts. Expl Parasitol 35:225–231
Dawson M, allan RJ, Watson TR (1982) The pharmacokinetics and bioavailability of mebendazole in man: a pilot study using 3H-mebendazole. Br J Clin Pharmacol 14:435–355
Eckert J, Barandun G, Pohlenz J (1978) Chemotherapie der larvalen Echinokokkose bei Labortieren. Schweiz Med Wochenschr 108:1104–1112
Eckert J, Pohlenz J (1976) Zur Wirkung von Mebendazol auf Metazestoden von Mesocestoides corti und Echinococcus multilocularis. Tropenmed Parasitol 27:247–62
Gemmell MA, Parmeter SN, Sutton RJ, Khan N (1981) Effect of mebendazole against Echinococcus granulosus and Taenia hydatigena cysts in naturally infected sheep and relevance to larval tapeworm infections in man. Z Parasitenkd 64:135–47
Jidejian Y (1953) Hydatid disease. Surgery 34:155–167
Kern P (1983) Human Echinococcosis: follow-up of 23 patients treated with mebendazole. Infection 11:17–24
Mancini G, Carbonara AO, Heremans JF (1965) Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 2:235–254
Nott DB (1979) Hydatid disease in man — past, present and future. Austr Vet J 55:136–139
Michiels M, Hendriks R, Heykants J (1978) A sensitive radioimmuno-assay for mebendazole (R 17635) and flubendazole (R 17889). Janssen research products information service. Preclinical Research Reports Nos. R 17635/11 and R 17889/9
Münst GJ, Karlaganis G, Bircher J (1980) Plasma concentrations of mebendazole during treatment of echinococcosis. Preliminary results. Eur J Clin Pharmacol 17:375–378
Reisin JL, Rabito CA, Rotunno CA, Cereijido M (1977) The permeability of the membranes of experimental secondary cysts of Echinococcus granulosus to (14C) mebendazole. Int J Parasitol 7:189–194
Schantz PM, Van den Bossche H, Eckert J (1982) Chemotherapy for larval echinococcosis in animals and humans: report of a workshop. Z Parasitkd 67:5–26
WHO (1981) FAO/UNEP/WHO Guidelines for surveillance, prevention and control of echinococcosis/hydatidos. Eckert J, Gemmell MA, Soulsby EJL (eds). World Health Organization, Geneva
Witassek F, Burkhardt B, Eckert J, Bircher J (1981) Chemotherapy of alveolar echinococcosis. Comparison of plasma mebendazole concentrations in animals and man. Eur J Clin Pharmacol 20:427–433
Witassek F, Allan RJ, Watson TR, Woodtli W, Ammann R, Bircher J (1983) Preliminary observations on the biliary elimination of mebendazole and its metabolites in patients with echinococcosis. Eur J Clin Pharmacol 25:81–84
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Luder, P.J., Witassek, F., Weigand, K. et al. Treatment of cystic echinococcosis (Echinococcus granulosus) with mebendazole: Assessment of bound and free drug levels in cyst fluid and of parasite vitality in operative specimens. Eur J Clin Pharmacol 28, 279–285 (1985). https://doi.org/10.1007/BF00543324
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00543324